Global /United States /Healthcare /Drug Manufacturers - Specialty & Generic /ANAS
chevron_leftBack
Alternaturals, Inc. logo

Alternaturals, Inc.

ANAS
OTCMKTS: ANAS Delayed
0.0199USD 0%
As of 19 June 2026, Alternaturals, Inc. has a market cap of $2.07M USD, ranking #47179 globally and #5992 in the United States. It ranks #4181 in the Healthcare sector, and #317 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
47179
Country Rank
5992
Sector Rank
4181
Industry Rank
317
Key Stats
Market Cap
$2.07MUSD
Net Income (TTM)
-$381.3KUSD
PB Ratio
0.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
25
Founded
1995
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0% 66% 17% 51% 165% 206%

News

Loading...

Markets

Exchange Ticker Price
OTC Markets
MIC: OTCM
PRIMARY
ANAS
Alternaturals Inc
ISIN: US02154R2094
Shares Out.:
104.247M1
TV:
SA:
YF:
GF:
BA:
MS:
0.0199 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Alternaturals, Inc.

Alternaturals, Inc. manufactures and distributes supplements and all-natural remedies that are alternatives to prescription drugs. Its products include Focamine, an all-natural focus, attention, and concentration promoter for people suffering from ADHD; and Sombium, an alternative sleep aid. The company was formerly known as Zhong Nong Yuan Fang Holdings, Inc. and changed its name to Alternaturals, Inc. in March 2022. Alternaturals, Inc. was incorporated in 1995 and is based in Reno, Nevada.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (United States)
Name
Market Cap diff.
PE
$29.56B
1M%
-
INDV
$2.06B
1.54B GBP
99K%
-
$2.06B
99K%
12.1
NDOI
$1.8B
87K%
0.4
$1.76B
85K%
-
$1.33B
64K%
-
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
PE
$37.2B
108.92B ILS
2M%
24.2
$15.88B
107.34B CNY
765K%
16.0
CIPLA
$11.25B
1.06T INR
542K%
23.4
LUPIN
$11.13B
1.05T INR
536K%
22.7
$9.11B
61.6B CNY
439K%
80.6
$8.73B
7.57B EUR
421K%
-
chevron_leftBack